Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1531956

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1531956

Global TROP2 Antibody Market & Clinical Trials Insight 2029

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3000
PDF (Multi-User License)
USD 5100

Add to Cart

Global TROP2 Antibody Market & Clinical Trials Insight 2029 Report Offering:

  • Global TROP2 Antibody Market Opportunity: > USD 3 Billion
  • Global & Regional Market Insight
  • Approved Drug Annual & Quarterly Sales By Region
  • Approved Drug Dosage & Pricing Insight
  • TROP2 Antibodies In Clinical Trials: > 45 Drugs
  • TROP2 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
  • Combination Approaches for TROP2 Antibody

TROP2 (trophoblast cell surface antigen 2) has recently gained prominence as target for cancer therapies due to its overexpression in a range of epithelial cancers, such as breast, lung, and urothelial cancers. This membrane protein, crucial for cell growth and survival, presents an appealing target for innovative treatments, especially antibody-drug conjugates (ADCs), which dominate the development pipeline. The landscape for TROP2- targeted therapies has experienced rapid evolution, marked by significant advancements and growing interest in harnessing this biomarker for more effective cancer treatment.

Currently, only one drug targeting TROP2 has been approved, namely Trodelvy (sacituzumab govitecan). Developed by Immunomedics (now part of Gilead Sciences), it received FDA approval in April 2020 for triple negative breast cancer and had its indication expanded to urothelial cancer in April 2021. As of August 2024, Trodelvy is approved in around 50 countries. Trodelvy's commercial success is evident from its significant sales growth. In the first half of 2024, sales jumped over 30% to surpass USD 600 million compared to the same period in 2023, driven mainly by increased demand for treatments in second-line metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer.

Datopotamab deruxtecan, another promising investigational TROP2-targeting drug developed by Daiichi Sankyo and AstraZeneca, has shown positive results in trials for various solid cancers. In the first half of 2024, both the FDA and EMA accepted applications for its Biologics License Application (BLA) and Marketing Authorization Application (MAA) for treating non-squamous non-small cell lung cancer and HR-positive, HER2-negative breast cancer. This progress highlights the growing interest in TROP2 as a therapeutic target and suggests the potential for more approved treatments soon.

The landscape of TROP2-targeted therapies is primarily characterized by antibody-drug conjugates (ADCs), which effectively merge the specificity of monoclonal antibodies with potent cytotoxic agents. This strategy facilitates the precise delivery of chemotherapy directly to cancer cells, thereby reducing systemic side effects. Although ADCs lead the way in TROP2-targeted therapies, other innovative methods are also under investigation. These include RNA-based therapies and cell therapies, which focus on altering TROP2 expression or leveraging the immune system to attack cancer cells that express TROP2.

The competitive environment surrounding TROP2 therapies is rapidly evolving, with a multitude of clinical trials currently in progress. Prominent pharmaceutical and biotechnology companies, such as Merck, Hansoh BioMedical, BiOneCure Therapeutics, Bio-Thera Solutions, Biohaven Therapeutics, and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, are making significant investments in this area. This heightened competition is fostering innovation and may expedite the introduction of new treatment alternatives for patients.

Notably, China is leading the TROP2 therapeutic landscape, showcasing a significant number of clinical trials and participating companies, with the US closely trailing behind. This development underscores the increasing significance of the Chinese biopharmaceutical sector and its commitment to pioneering cancer treatments. The international scope of TROP2 research and development indicates that patients around the globe may soon have access to these innovative therapies.

As the field progresses, several key factors will be crucial for advancing TROP2-targeted therapies. Extensive long-term data on the efficacy and safety of both approved and experimental treatments will be essential for integrating these therapies into standard protocols and achieving broader acceptance. Identifying biomarkers for patient stratification will be critical to enhance treatment outcomes and ensure therapies are administered to those most likely to benefit. Additionally, understanding resistance mechanisms to TROP2-targeted therapies will be vital for developing strategies to mitigate or prevent resistance, potentially through combination therapies or next-generation agents.

The rapid development of therapies targeting TROP2 marks a notable progression in the field of precision oncology. As additional data is gathered from ongoing clinical trials and the practical application of approved treatments, the comprehensive potential of TROP2 targeting in cancer management will become more evident. The achievements observed to date indicate that TROP2-targeted therapies could assume a more prominent position in the treatment of diverse epithelial cancers, thereby enhancing outcomes for patients who have few treatment alternatives.

Table of Contents

1. Introduction to TROP2 Targeting Therapy Market

  • 1.1 Overview
  • 1.2 TROP2 Targeting Therapeutics Mechanism
  • 1.3 TROP2 Ideal Clinical Biomarker for Cancer

2. TROP2 Targeted Antibodies Ongoing Clinical Trials Insight

  • 2.1 By Company
  • 2.2 By Country
  • 2.3 By Patient Segment
  • 2.4 By Phase
  • 2.5 By Priority Status

3. Global TROP2 Antibody Market Outlook

  • 3.1 Current Market Scenario
  • 3.2 Future Market Opportunities

4. Trodelvy (Sacituzumab Govitecan) - First Approved TROP2 Targeting Antibody

  • 4.1 Overview
  • 4.2 Approval, Patent & Exclusivity

5. Trodelvy (Sacituzumab Govitecan) - Commercial Insight

  • 5.1 Dosage & Price Analysis
  • 5.2 Sales Analysis (2020 - 2024)

6. Unveiling TROP2 Therapeutic Frontiers Market Trend By Region

  • 6.1 US
  • 6.2 China
  • 6.3 Australia
  • 6.4 South Korea
  • 6.5 Europe
  • 6.6 Taiwan
  • 6.7 Japan

7. Global TROP2 Targeting Antibodies Market by Cancer

  • 7.1 Breast Cancer
  • 7.2 Lung Cancer
  • 7.3 Gastric Cancer
  • 7.4 Urothelial Cancer
  • 7.5 Ovarian Cancer

8. TROP2 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase I
  • 8.4 Phase I/II
  • 8.5 Phase II
  • 8.6 Phase III
  • 8.7 Preregistration

9. Marketed TROP2 Antibody Clinical Insight

10. Combination Approaches for TROP2 Antibody

11. Competitive Landscape

  • 11.1 Abion Bio
  • 11.2 Amunix
  • 11.3 Aptamer Sciences
  • 11.4 Arbele
  • 11.5 Aston Science
  • 11.6 AstraZeneca
  • 11.7 Beijing Biocytogen
  • 11.8 BiOneCure Therapeutics
  • 11.9 Biosion
  • 11.10 Bio-Thera Solutions
  • 11.11 Daiichi Sankyo Company
  • 11.12 Hangzhou DAC Biotech
  • 11.13 Innovent Biologics
  • 11.14 Janux Therapeutics
  • 11.15 LegoChem Biosciences
  • 11.16 Merck
  • 11.17 Molecular Templates
  • 11.18 OBI Pharma
  • 11.19 Peak Bio
  • 11.20 Radiopharm Theranostics
  • 11.21 Shanghai Henlius Biotech
  • 11.22 Suzhou GeneQuantum Healthcare

List of Figures

  • Figure 1-1: Evolution of TROP2 Targeting Therapeutics
  • Figure 1-2: TROP2 Stimulated Effectors, Biomarker & Pathways
  • Figure 1-3: TROP2 Regulated Oncogenic Cell Signaling Pathways
  • Figure 1-4: General Mechanism of TROP2 Targeting Therapy
  • Figure 1-5: Trodelvy - Mechanism of Action
  • Figure 1-6: Frequency of TROP2 Expression by Cancer Type (%)
  • Figure 1-7: Role of TROP2 in Cancer
  • Figure 2-1: Global -TROP2 Antibodies Clinical Pipeline By Company, 2024 - 2029
  • Figure 2-2: Global -TROP2 Antibodies Clinical Pipeline By Country, 2024 - 2029
  • Figure 2-3: Global -TROP2 Antibodies Clinical Pipeline By Patient Segment, 2024 - 2029
  • Figure 2-4: Global -TROP2 Antibodies Clinical Pipeline By Phase, 2024 - 2029
  • Figure 2-5: Global -TROP2 Antibodies Clinical Pipeline By Priority Status, 2024 - 2029
  • Figure 3-1: Global - TROP2 Antibody Market (US$ Million), 2020-2024
  • Figure 3-2: Global - TROP2 Antibody Market (US$ Million), Q1 - Q2'2024
  • Figure 3-3: Global - TROP2 Antibody Market by Region (US$ Million), H1'2024
  • Figure 3-4: Global - TROP2 Antibody Market by Region (%), H1'2024
  • Figure 3-5: Phase 3 - Key TROP2 Drugs & Companies
  • Figure 3-6: Gilead Secures Investment From Abingworth To Fund Trodelvy Trials
  • Figure 3-7: Future TROP2 Market
  • Figure 3-8: Global - TROP2 Antibodies Market (US$ Million), 2024-2029
  • Figure 4-1: Trodelvy - FDA Approval Year by Indication
  • Figure 4-2: Trodelvy - Patent Expiration Year by Region
  • Figure 4-3: Trodelvy - Approval Year by Region
  • Figure 4-4: Trodelvy - FDA Orphan Designation Year by Indication
  • Figure 5-1: US - Price of 180mg Vial of Trodelvy Intravenous Powder (US$), August'2024
  • Figure 5-2: EU - Price of 180mg & 200mg Vials of Trodelvy Intravenous Powder (US$), August'2024
  • Figure 5-3: Global - Trodelvy Sales (US$ Million), 2020-2024
  • Figure 5-4: Global - Trodelvy Sales (US$ Million), Q1 - Q2'2024
  • Figure 5-5: Regional -Trodelvy Sales by Region (US$ Million), H1'2024
  • Figure 5-6: Trodelvy Sales by Region (%), H1'2024
  • Figure 5-7: US -Trodelvy Sales (US$ Million), Q1 - Q2'2024
  • Figure 5-8: Europe - Trodelvy Sales (US$ Million), Q1 - Q2'2024
  • Figure 5-9: ROW - Trodelvy Sales (US$ Million), Q1 - Q2'2024
  • Figure 5-10: US -Trodelvy Sales (US$ Million), 2021-2024
  • Figure 5-11: Europe - Trodelvy Sales (US$ Million), 2021-2024
  • Figure 5-12: ROW - Trodelvy Sales (US$ Million), 2021-2024
  • Figure 5-13: Global - Trodelvy Sales (US$ Million), Q1- Q4'2023
  • Figure 5-14: Trodelvy - Sales By Region (US$ Million), 2023
  • Figure 5-15: Trodelvy - Sales By Region (%), 2023
  • Figure 5-16: US - Trodelvy Sales (US$ Million), Q1 - Q4'2023
  • Figure 5-17: Europe - Trodelvy Sales (US$ Million), Q1 - Q4'2023
  • Figure 5-18: ROW - Trodelvy Sales (US$ Million), Q1 - Q4'2023
  • Figure 6-1: China TROP2 - Key Players & Drugs
  • Figure 6-2: FDA018-ADC Phase III Study (NCT06519370) - Initiation & Completion Year
  • Figure 6-3: SHR-A1921 Phase III Study (NCT06394492) - Initiation & Completion Year
  • Figure 6-4: FZ-AD004 Phase I Study (NCT05914545) - Initiation & Completion Year
  • Figure 6-5: Trodelvy - TGA Priority Review for HR+/HER2 Metastatic Breast Cancer
  • Figure 6-6: MT-302 Phase I Study (NCT05969041) - Initiation & Completion Year
  • Figure 6-7: Radiopharm Theranostics & Lantheus Holdings Agreement
  • Figure 6-8: South Korea - Key TROP2 Companies
  • Figure 6-9: LegoChem Biosciences (LCB) & Johnson & Johnson Collaboration
  • Figure 6-10: LCB84 with an Anti-PD-1 Antibody Phase I/II Study (NCT05941507) - Initiation & Completion Year
  • Figure 6-11: Dato-DXd Received two EMA marketing authorization applications (MAAs)
  • Figure 6-12: DB-1305/BNT325 Phase I/II Study (NCT05438329) - Initiation & Completion Year
  • Figure 6-13: Mediterranea TROP2 antibody, Hu-2G10
  • Figure 6-14: OBI Pharma TROP2 Therapy Pipeline
  • Figure 6-15: OBI-992 Phase I/II Study (NCT06480240) - Initiation & Completion Year
  • Figure 6-16: Dato-DXd & Durvalumab Phase III Study (NCT06112379) - Initiation & Completion Year
  • Figure 7-1: Breast Cancer - Estimated & Projected Cases, 2022 & 2030
  • Figure 7-2: Lung Cancer - Estimated & Projected Cases, 2022 & 2030
  • Figure 7-3: TROPION-Lung01 Phase 3 Study - Initiation & Completion Year
  • Figure 7-4: EVOKE-01 Phase 3 Study - Initiation & Completion Year
  • Figure 7-5: EVOKE-03 Phase 3 Study - Initiation & Completion Year
  • Figure 7-6: EVOKE-02 Phase 2 Study - Initiation & Completion Year
  • Figure 7-7: Gastrointestinal Cancer - Estimated & Projected Cases, 2022 & 2030
  • Figure 7-8: MK-2870-015 Phase 3 Study - Initiation & Completion Year
  • Figure 7-9: MK-3475-06C Phase 1/2 Study - Initiation & Completion Year
  • Figure 7-10: KL264-01 Phase 1/2 Study - Initiation & Completion Year
  • Figure 7-11: Urothelial Cancer - Estimated & Projected Cases, 2022 & 2030
  • Figure 7-12: Urothelial Cancer - Estimated & Projected Cases, 2022 & 2030
  • Figure 7-13: BNT-325 (NCT05438329) Phase 1/2 Study - Initiation & Completion Year
  • Figure 10-1: TROP2 Antibodies Combinations

List of Tables

  • Table 5-1: Trodelvy - Dose Modifications for Adverse Reactions
  • Table 6-1: US - Some Clinical Trials Assessing TROP2 Targeting Therapies
  • Table 6-2: China - Ongoing Clinical Trial for TROP2 Therapies
  • Table 6-3: SKB264 (MK-2870) - NMPA Designations, Indications & Year Insight
  • Table 6-4: Preclinical TROP2 Candidates Development in China
  • Table 6-5: Australia - Ongoing Clinical Trial for TROP2 Therapies
  • Table 6-6: South Korea - Ongoing Clinical Trial for TROP2 Therapies
  • Table 6-7: Europe - Ongoing Clinical Trial for TROP2 Therapies
  • Table 6-8: Taiwan - Ongoing Clinical Trial for TROP2 Therapies
  • Table 6-9: Japan - Ongoing Clinical Trial for TROP2 Therapies
  • Table 7-1: Breast Cancer - TROP2 ADC under Review
  • Table 7-2: Breast Cancer - Some TROP2 Targeted Candidates in Development
  • Table 7-3: Lung Cancer - TROP2 ADC under Review
  • Table 7-4: Lung Cancer - Some TROP2 Targeted Candidates in Development
  • Table 7-5: Gastric Cancer - Some TROP2 Targeted Candidates in Development
  • Table 7-6: Urothelial Cancer -Key TROP2 Targeted Candidates in Development
  • Table 7-7: Urothelial Cancer - Key TROP2 Targeted Candidates in Development
  • Table 10-1: Ongoing Preclinical & Clinical trials for Combination of TROP2 Therapy
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!